Investigating how nonneuronal cells contribute to brain degeneration in a genetic disorder.
Nonneuronal Mechanisms of Polyglutamine Neurodegeneration
This study is looking at Spinocerebellar Ataxia type 3 (SCA3) to understand how changes in a specific gene affect the brain and cause problems, with the hope of finding new treatments for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10873342 on NIH RePORTER |
What this research studies
This research focuses on Spinocerebellar Ataxia type 3 (SCA3), a genetic disorder caused by abnormal expansions in a specific gene. The team aims to understand how these genetic changes lead to brain dysfunction and cell death, particularly looking at the role of oligodendrocytes, a type of nonneuronal cell in the brain. By using various models, including mouse models and human tissue, the researchers will explore the mechanisms behind the disease and identify potential targets for new therapies. This could lead to breakthroughs in treating SCA3 and similar conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Spinocerebellar Ataxia type 3 or related polyglutamine diseases.
Not a fit: Patients with other forms of ataxia or neurodegenerative diseases not related to polyglutamine expansions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat or manage Spinocerebellar Ataxia type 3 and related disorders.
How similar studies have performed: Previous research has shown promise in understanding the role of nonneuronal cells in neurodegeneration, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Mcloughlin, Hayley Sarah — University of Michigan at Ann Arbor
- Study coordinator: Mcloughlin, Hayley Sarah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.